Identification of gp96 as a novel target for treatment of autoimmune disease in mice

39Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

Abstract

Heat shock proteins have been implicated as endogenous activators for dendritic cells (DCs). Chronic expression of heat shock protein gp96 on cell surfaces induces significant DC activations and systemic lupus erythematosus (SLE)-like phenotypes in mice. However, its potential as a therapeutic target against SLE remains to be evaluated. In this work, we conducted chemical approach to determine whether SLE-like phenotypes can be compromised by controlling surface translocation of gp96. From screening of chemical library, we identified a compound that binds and suppresses surface presentation of gp96 by facilitating its oligomerization and retrograde transport to endoplasmic reticulum. In vivo administration of this compound reduced maturation of DCs, populations of antigen presenting cells, and activated B and T cells. The chemical treatment also alleviated the SLE-associated symptoms such as glomerulonephritis, proteinuria, and accumulation of anti-nuclear and -DNA antibodies in the SLE model mice resulting from chronic surface exposure of gp96. These results suggest that surface translocation of gp96 can be chemically controlled and gp96 as a potential therapeutic target to treat autoimmune disease like SLE. © 2010 Han et al.

Cite

CITATION STYLE

APA

Han, J. M., Kwon, N. H., Lee, J. Y., Jeong, S. J., Jung, H. J., Kim, H. R., … Kim, S. (2010). Identification of gp96 as a novel target for treatment of autoimmune disease in mice. PLoS ONE, 5(3). https://doi.org/10.1371/journal.pone.0009792

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free